Volpara Health Technologies Ltd.

Based in Wellington, New Zealand, Volpara Health Technologies Ltd. , previously known as Matakina Technology Limited, specializes in intelligent breast screening software designed to combat advanced-stage breast cancer. In December 2024, Lunit Inc. , a portfolio company of Softbank Ventures Asia and Guardant Health, Inc.

, agreed to acquire Volpara Health Limited for KRW 252. 5 billion at KRW 993. 522 per share. As of April 2022, the company is led by CEO Teri Thomas.

  Volpara Health Limited offers intelligent breast screening software that is seamlessly integrated into medical workflows. The company uses advanced AI technology to provide clinical decision support, offering evidence-based insights for informed care decisions. The software employs AI-powered tools to optimize breast imaging, offering insights into breast cancer risk through advanced models like Tyrer-Cuzick modeling. Volpara's software optimizing program performance, mammography quality, and productivity analysis enhances the efficiency of breast screening programs, ensuring a comprehensive and tailored approach to healthcare.

In addition, the firm’s Volpara Lung software system is designed to enhance lung screening workflows. From patient scheduling to diagnosis, the platform streamlines the management process, allowing healthcare providers to easily submit, validate, and check the status of patient data, expediting reimbursement. The software provides real-time patient insights through statistical reports, aiding in effective lung cancer screening. The features include nodule tracking for managing incidental findings and customizable report templates, which accommodate essential COVID-19 patient information.